Background
Phase 1–2 open-label prospective single-arm study. 27 patients with telomere diseases — defined by short telomeres (<1st percentile for age) and/or pathogenic mutations in telomere-related genes (TERT, TERC, DKC1, RTEL1, etc.) — enrolled at the NIH. Diagnoses included dyskeratosis congenita (DKC), aplastic anemia, pulmonary fibrosis, and liver cirrhosis. Median age 41 years (range 17–66). Premise: sex hormone analogues upregulate telomerase gene expression in hematopoietic cells.
Interventions and follow up
Regimen: Danazol 800 mg/day orally for 24 months (single arm, no comparator)
Primary endpoint: ≥20% reduction in annual rate of telomere attrition at 24 months
Median follow up: 27 months
Primary endpoint: ≥20% reduction in annual rate of telomere attrition at 24 months
Median follow up: 27 months
Results
Primary endpoint met: 12/27 (44%; 95% CI 26–64%) — trial halted early because all 12 evaluable patients met the endpoint
Telomere length change at 24 months: 11/12 (92%) had telomere gain; mean increase 386 bp (95% CI 178–593)
Hematologic response: 19/24 (79%) at 3 months; 10/12 (83%) at 24 months
Transfusion independence: 12/13 transfusion-dependent patients became transfusion-independent
Telomere length change at 24 months: 11/12 (92%) had telomere gain; mean increase 386 bp (95% CI 178–593)
Hematologic response: 19/24 (79%) at 3 months; 10/12 (83%) at 24 months
Transfusion independence: 12/13 transfusion-dependent patients became transfusion-independent
Adverse events
Hepatic: grade ≤2 elevated liver enzymes in 41%
Musculoskeletal: muscle cramps grade ≤2 in 33%
Endocrine/other: virilization expected with danazol in female patients (hair growth, voice changes); no grade ≥3 unexpected toxicities; no treatment-related deaths
Musculoskeletal: muscle cramps grade ≤2 in 33%
Endocrine/other: virilization expected with danazol in female patients (hair growth, voice changes); no grade ≥3 unexpected toxicities; no treatment-related deaths
Conclusions
Danazol 800 mg/day for 24 months led to telomere elongation and hematologic improvement in patients with telomere diseases including DKC and related bone marrow failure. The unexpected finding of actual telomere elongation (not just attenuated loss) was the key discovery, establishing danazol as a disease-modifying agent for telomere biology disorders.
Key Limitations
Design: single-arm with no comparator — spontaneous fluctuation in telomere length or counts cannot be excluded; halted early on unplanned interim analysis
Population: small N=27, highly selected NIH cohort; different telomere-related mutations may respond differently
Safety: long-term effects and transformation risk of prolonged androgen use unknown; virilizing and hepatotoxic effects limit use, particularly in women
Population: small N=27, highly selected NIH cohort; different telomere-related mutations may respond differently
Safety: long-term effects and transformation risk of prolonged androgen use unknown; virilizing and hepatotoxic effects limit use, particularly in women
Clinical Context
Danazol and other androgens are now established second-line therapy for bone marrow failure in DKC and telomere disorders when transplant is not feasible or desired; this trial provided the first prospective evidence of pharmacologic telomere elongation. Combined with eltrombopag data (Olnes 2012), androgen and TPO-agonist strategies are explored in non-severe aplastic anemia with underlying telomere defects. No specific FDA approval for DKC, but use is guideline-supported.